Details

Autor(en) / Beteiligte

• Maenhout, Metha
• Peters, Max
• Moerland, Marinus A.
• Meijer, Richard P.
• van den Bosch, Maurice A.A.J.
• Frank, Steven J.
• Nguyen, Paul L.
• van Vulpen, Marco
• van der Voort van Zyp, Jochem R.N.

Titel

MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life

Ist Teil von

• Radiotherapy and oncology, 2018-12, Vol.129 (3), p.554-560

Ort / Verlag

Ireland: Elsevier B.V

Erscheinungsjahr

2018

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• To describe toxicity, biochemical outcome and quality of life after MRI guided focal high dose rate brachytherapy (HDR-BT) in a single fraction of 19 Gy for localized prostate cancer. Between May 2013 and April 2016, 30 patients were treated by MRI-guided focal HDR-BT. Patients with visible tumour on MRI were included. All patients were ≥65 years, T-stage <T3, Gleason ≤7, PSA <10 ng/mL and IPSS <15. Focal irradiation was delivered in a single fraction of 19 Gy to the D95 of the clinical target volume. Toxicity was reported using the Common Terminology Criteria for Adverse Events version 4. Biochemical failure was defined according to the Phoenix criteria and quality of life was measured using validated questionnaires. Median follow up was 24 months. One patient developed a grade 2 and 3 GU toxicity after treatment. In the other 29 patients, no grade 2 or higher perioperative complications occurred. Five patients developed a biochemical recurrence. For all measured time points, there was no statistically significant deterioration in quality of life. Focal MRI guided HDR-BT confers low toxicity rates and maintains quality of life. Biochemical recurrence is rather high, 5 patients developed a biochemical recurrence according to the Phoenix definition. Longer evaluation of these patients is necessary and caution is warranted before implementing focal HDR-BT in patients with localized prostate cancer.